iShares 3 7 Year Treasury Bond ETF vs Stryker Corporation — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.49 (market cap $16.72B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 6.4× iShares 3 7 Year Treasury Bond ETF's market cap, and Stryker Corporation pays a 1.27% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Stryker Corporation for 21 Days on average.
| IEI | SYK | |
|---|---|---|
Market Cap | $16.72B | $106.24B |
Volume | 3,963,319 | 2,982,001 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $388.35 |
52-Week Low | $113.17 | $269.75 |
Typical Hold Time | 43 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.57 with minimal daily movement (+0.17%), showing stability amid broader market volatility. The technical picture remains bearish with moving averages signaling downward pressure, though oscillators suggest neutral momentum. Recent dividend payments of $0.37-0.38 per share demonstrate consistent shareholder returns. The stock faces headwinds from rising Treasury yields and bond market volatility, which could impact investor appetite for equities.
Outlook remains cautious as higher interest rates and bond market turbulence create challenging conditions. The bearish technical signals and neutral fundamental metrics suggest limited near-term upside potential. Key risks include continued bond market volatility and macroeconomic pressures, though consistent dividend payments provide some defensive characteristics for income-focused investors.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Trailing returns across standard periods
Latest headlines on both assets
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →